U.S. monkeypox cases reach 10,000, CDC still aiming for 'containment'

Currently, 10,000 Americans have tested positive for monkeypox outbreaks nationwide according to figures released late Wednesday by the Centers for Disease Control and Prevention . to contain the virus.

All states except Wyoming have reported cases, and 15 states and the District of Columbia have reported more than 100 cases. The most common are New York, California, and Florida.

The World Health Organization has tallied monkeypox deaths so far this year at 12, and no deaths have been reported in the United States so far. . 

Health officials say the virus is spread primarily through close interactions between men who have sex with men. That's it. Skin contacts or shared linens such as towels and bedding. 

However, the CDC has tallied at least 50 cases in people who were female at birth, including at least one pregnant womanA small number of suspected infections. It has also been found in premature infants, but health officials recently said some may actually be false positives. 

has warned it expects the outbreak in the United States to accelerate until August. Year. 

The United States has reportedmore infections than any othercountry in the world since late July. The number of cases in the United States is now roughly twice as large as Spain, aEuropean country, and previously reported more cases than Germany and the United Kingdom.

Currently, the pace of new cases appears to be slowing in some countries abroad. Measured relative to the size of the country's population, the CDC's tally is still smaller than those of these European countries, but the accelerating US outbreak is now appearing at a pace above these rates. 

In states with more than 25 cases, CDC officials estimate that the rate of new monkeypox infections has recently doubled on average every 8.6 days. . 

On Wednesday, 1,391 new cases were reported to CDC nationwide. This is her biggest one-day gain to date. The first known cases in the current US outbreak were reported in mid-May.

"While we are still operating under containment goals, many states are now in mitigation phases given our case numbers are still rising rapidly. I know you're starting to wonder if we're going to move to ." Jennifer McKiston, the CDC's chief monkeypox officer, told a group of external advisors at the agency on Tuesday.

This effort will be facilitated in the coming weeks, following the Food and Drug Administration's grant of Emergency Use Authorization this week for the use of low-dose Gynneos monkeypox vaccine. may become. By administering small amounts of these between layers of the skin, rather than deep in the arm,we were able to effectively increase the supply of shots in the United States 

It might be possible to vaccinate up to five times as many people with each vial, and still get"nearly the same"immune responses. increase.

However, the CDC has long warned There is limited data showing that the Jynneos vaccine actually reduces monkeypox disease and transmission. Infection during an outbreak”. 

FDA reports on several reports of breakthrough infections after receiving at least one dose of her Jynneos vaccine prior to two doses Did. Early data from France,where the vaccine is branded as Imvanex, also tallied breakthrough infections.

Local health authorities will take time to ramp up new 'intradermal'vaccination approaches that rely on needles and procedures that differ from traditional 'subcutaneous' injections. warned. 

"We don't say 'begin'. We make sure people have updated provider contracts, updated training requirements, all of this. And , as you know, the first call with the CDC about this will be on Friday. Official Dr. Alison Arwady. 

Arwady, deputy chairman of the Big Cities Health Coalition, said that the national estimated that it could take up to three weeks. - Humble approach.

CDC does not currently encourage "mass vaccinations for the general public or all sexually active people" due to limited supplies. Instead, government agencies are prioritizing immunization for people living with HIV, pregnant women, the very young,and those considered to be at high risk for serious illness. 

But while supply is now growing in response to the FDA's move, McQuiston said the CDC will soon have a broader scope. 

Authorities are also considering using the older ACAM2000 vaccine, but there are concerns that it has more side effects and risks than Jynneos. 

“There are millions of doses of ACAM2000 in this system. It suggests that it could play an important role in the